As a very big JDRF supporter, I am extremely happy to share some JDRF insider news on their work of creating an artificial pancreas, another huge step in making the lives of type 1 diabetics much easier. Click here if you would like to make a donation to support JDRF.
JDRF-Funded AP Technology Receives $12.7 Million Clinical Development Grant from the National Institutes of HealthToday we celebrate a significant achievement that advances delivery of artificial pancreas (AP) technology to the type 1 diabetes (T1D) community.Over the past decade, JDRF has provided more than $3.5 million to support the development of AP technology by University of Virginia (UVA) researchers. That technology has now taken a major step towards commercialization with the research team announcing that its inControl AP platform will be tested in a multi-center, $12.7 million clinical trial funded by the National Institutes of Health using money from its Special Diabetes Program, which JDRF persuaded Congress to renew last year. The trial is set to begin early this year. The research team also has licensed its inControl AP platform to the startup TypeZero Technologies for the purpose of commercializing the software should it receive FDA approval. This important accomplishment would not have been possible without help from our many supporters. We are extremely grateful to our donors, partners and the entire T1D community.
The inControl AP software is an algorithm that links insulin pumps and continuous glucose monitors to automate insulin delivery in a manner that prevents dangerous blood sugar highs and lows in people with T1D. Over the past decade, JDRF has supported development of UVA’s project and other AP technology by creating the JDRF AP Consortium, providing more than $100 million in funding support and working with the U.S. Food and Drug Administration to develop a pathway for AP systems approval. UVA lead researcher Boris Kovatchev, Ph.D., has publicly acknowledged JDRF’s role in helping to advance the UVA project.
The advancement of the inControl AP platform could play an important role in delivering highly reliable, effective AP systems that keep blood sugar within a safe and healthy range with little monitoring and action on the part of the user. It’s an important step towards creating a world without T1D, made possible by JDRF supporters. Email questions to email@example.com.